Abstract:Introduction: HCC is an aggressive and genetic heterogeneous disease. Several disrupted signaling pathways have been identified, though actionable targets are limited. The majority of systemic chemotherapy and targeted therapy (tyrosine kinase inhibitors (TKIs) or monoclonal antibodies) have demonstrated minimal to no clinical activity. Immunotherapy has emerged as a potentially transformative strategy with attractive and long-lasting responses in HCC. However, the clinical efficacy of immune check point blockades (ICB) is limited to a select subset of patients and is hampered by drug resistance. Methods: In this study, we focused on tumor cell intrinsic factors and conducted a hybridization-capture methodology and targeted 1 Mb of genomic coding sequence ( Gene Plus1021 Panel). Analysis of 81 HCC tumors and matching plasma normal samples was performed to characterize the landscape of somatic mutations especially those related to the sensitivity, resistance and hyper progression of ICB therapy in HCC. For genes identified in our study significantly correlated with tumor mutational burden (TMB), We further did the verification in The Cancer Genome Atlas (TCGA)-LIHC. 363 HCC tumor samples were included in the cohort and the data was downloaded from cBioPortal website (http://www.cbioportal.org/). Results: We analyzed 81 HCC tumor samples accepted in Peking University International Hospital from January 2015 to Jun 2018 who did not receive ICB therapy at the time of taking specimen. The top quartile (7 muts/Mb) of TMB distribution was used as the cutoff value to define high tumor mutational burden (TMB-H). There were 26 cases (32.10%) with high TMB. Among all the 81 samples analyzed we detected no mismatch repair deficiency (dMMR), but identified five gene mutations having a significant correlation with high TMB including TP53, CTNNB1, ARID1A, MLL and NCOR1, p=0.0439, 0.0196, 0.0023, 0.0247 and 0.0076, retrospectively. We further did the verification in The Cancer Genome Atlas (TCGA)-LIHC. Gene mutations of TP53, CTNNB1, and MLL were proved to be highly associated with TMB-H status, p=0.0009, 0.0016 and 0.0013, retrospectively. Moreover, gene mutations of ARID1A, TP53 and MLL were proved to implicate poor overall survival. We detected 2 mutations (2.47%) in POLE, 2 mutations (2.47%) in PTEN, 1 mutation (1.23%) in DNMT3A, and 1 sample (1.23%) with high microsatellite instability (MSI-H). TMB value for the only one sample in MSI-H status was 9 muts/Mb (TMB-H). Instead of dMMR, one TP53 mutation and one ARID1A mutation were detected in this sample. Conclusions: TMB-high and crucial driver gene mutations associated with high mutation load should be evaluated as potential predictive biomarkers in datasets of HCC patients treated with ICB therapy. Note: This abstract was not presented at the meeting. Citation Format: Li Li, Zhaohong Wen, Michael J. Overman, Xiaosong Rao, Yuting Yi, Yanfang Guan, Jun Liang. Identification of mutational landscape predicting efficacy of immune checkpoint blockades and recurrent mutations related to high tumor mutational burden in hepatocellular carcinoma by next generation sequencing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1255.

High Tumor Mutational Burden in Hepatocellular Carcinoma

Based on Tumor Mutation Burden to construct diagnosis and prognosis models and provides guidance for the treatment in the Hepatocellular Carcinoma patients

Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden

Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma

Tumor Mutation Burden Analysis in a 5,660 Cancer Patient Cohort Reveals Cancer Type-Specific Mechanisms for High Mutation Burden.

Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.

Abstract 1255: Identification of Mutational Landscape Predicting Efficacy of Immune Checkpoint Blockades and Recurrent Mutations Related to High Tumor Mutational Burden in Hepatocellular Carcinoma by Next Generation Sequencing

Tumor-Associated Neutrophils: an Emerging Player in the Immune Microenvironment of Hepatocellular Carcinoma

High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma

Implications of Driver Genes Associated with a High Tumor Mutation Burden Identified Using Next-Generation Sequencing on Immunotherapy in Hepatocellular Carcinoma.

Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis

Prognostic Analysis of Tumor Mutation Burden and Immune Infiltration in Hepatocellular Carcinoma Based on TCGA Data

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

High Tumor Mutation Burden Predicts Better Efficacy of Immunotherapy: a Pooled Analysis of 103078 Cancer Patients.

Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma

Mutational landscape and tumor mutation burden (TMB) feature of biliary cancer.

High Tumor Mutational Burden May Predict Improved Response to Immunotherapy in Head and Neck Cancer Patients

Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma

Comprehensive analysis of TMB, TNB, and HLA via NGS sequencing in a large cohort of Chinese pan-cancer patients.

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis